Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman's disease
jRCT2051200050Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sirolimus in idiopathic multicentric Castleman disease (iMCD), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Incidence of adverse events. Started Oct 2020; status: completed.
02
Drugs
sirolimus
03
Conditions
idiopathic multicentric Castleman disease (iMCD)
Beyond the preview
Go deeper on jRCT2051200050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200050.